Israel - English - Ministry of Health

alexion pharma israel ltd - eculizumab - concentrate for solution for infusion - eculizumab 10 mg/ml - eculizumab - eculizumab - soliris is indicated for the treatment of patients with: - paroxysmal nocturnal haemoglobinuria (pnh). evidence of clinical benefit is demonstrated in patients with haemolysis with clinical symptom(s) indicative of high disease activity, regardless of transfusion history. eculizumab has not been studied in clinical trials in patients with pnh below 11 years of age.- atypical haemolytic uremic syndrome (ahus).soliris is indicated in adults for the treatment of: - refractory generalized myasthenia gravis (gmg) in patients who are anti-acetylcholine receptor (achr) antibody-positive.-neuromyelitis optica spectrum disorder (nmosd) in patients who are anti-aquaporin-4 (aqp4) antibody-positive with a relapsing course of the disease who have received prior therapy.

Israel - English - Ministry of Health

alexion pharma israel ltd - ravulizumab - concentrate for solution for infusion - ravulizumab 10 mg/ml - ravulizumab - ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with paroxysmal nocturnal haemoglobinuria (pnh): • in patients with haemolysis with clinical symptom(s) indicative of high disease activity. • in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.ultomiris is indicated in the treatment of adult patients with generalized myasthenia gravis (gmg) who are anti-acetylcholine receptor (achr) antibody-positive.

Israel - English - Ministry of Health

alexion pharma israel ltd - asfotase alfa - solution for injection - asfotase alfa 100 mg / 1 ml - asfotase alfa - strensiq is indicated for long-term enzyme replacement therapy in patients with paediatric-onset hypophosphatasia to treat the bone manifestations of the disease.

Israel - English - Ministry of Health

alexion pharma israel ltd - asfotase alfa - solution for injection - asfotase alfa 40 mg / 1 ml - asfotase alfa - strensiq is indicated for long-term enzyme replacement therapy in patients with paediatric-onset hypophosphatasia to treat the bone manifestations of the disease.

Canada - English - Health Canada

alexion pharma gmbh - eculizumab - solution - 10mg - eculizumab 10mg - complement inhibitors

Canada - English - Health Canada

alexion pharma gmbh - selumetinib (selumetinib sulfate) - capsule - 10mg - selumetinib (selumetinib sulfate) 10mg

Canada - English - Health Canada

alexion pharma gmbh - selumetinib (selumetinib sulfate) - capsule - 25mg - selumetinib (selumetinib sulfate) 25mg

Canada - English - Health Canada

alexion pharma gmbh - ravulizumab - solution - 10mg - ravulizumab 10mg - immunosuppressive agents

Canada - English - Health Canada

alexion pharma gmbh - ravulizumab - solution - 300mg - ravulizumab 300mg

Canada - English - Health Canada

alexion pharma gmbh - ravulizumab - solution - 1100mg - ravulizumab 1100mg